{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:22:32Z","timestamp":1756902152827,"version":"3.44.0"},"reference-count":26,"publisher":"The Pediatric Pharmacy Association","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVES<\/jats:title>\n                  <jats:p>Constipation is a common adverse event of opioid use that is often difficult to treat. Methylnaltrexone is a therapeutic option for opioid-induced constipation (OIC) approved for oral and subcutaneous use in adults. These administration routes are not always feasible in the pediatric population. The primary objective of this research was to quantify the response rate of methylnaltrexone in pediatric patients when it was administered via the intravenous (IV) route.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>This retrospective study evaluated patients ages &amp;lt;18 years who received IV methylnaltrexone between January 1, 2013, and June 30, 2020, for OIC. Efficacy was evaluated through documentation of bowel evacuation within 4 hours of methylnaltrexone administration. Adverse events observed within 24 hours of administration were attributed to methylnaltrexone.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Methylnaltrexone was administered to 134 unique patients during the study period. Of these, 46 met exclusion criteria, resulting in 88 patients being included in the study. Patients with an underlying hematology\/oncology diagnosis consisted of 77% of the study population, and 23% of patients had an \u00adunderlying medical\/surgical diagnosis. The response rate to IV methylnaltrexone was 25% (CI, 16\u201334).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>The results of this retrospective chart review demonstrate the potential role of IV methylnaltrexone in the pediatric population. Despite the overall lower response rate relative to that reported in adults, IV methylnaltrexone possesses a unique mechanism of action that may serve as an alternative treatment option for patients unable to use the oral and subcutaneous administration routes. There were no significant adverse events seen in the study.<\/jats:p>\n               <\/jats:sec>","DOI":"10.5863\/1551-6776-29.3.292","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T18:38:02Z","timestamp":1718044682000},"page":"292-298","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Outcomes of Intravenous Methylnaltrexone in Children: A Single-Arm Retrospective Cohort Study"],"prefix":"10.5863","volume":"29","author":[{"given":"Michael","family":"Raschka","sequence":"first","affiliation":[{"name":"Department of Pharmacy (MR, KG, ML), Children\u2019s Minnesota, Minneapolis, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayla","family":"Gahr","sequence":"additional","affiliation":[{"name":"Department of Pharmacy (MR, KG, ML), Children\u2019s Minnesota, Minneapolis, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dave","family":"Watson","sequence":"additional","affiliation":[{"name":"Research Institute (DW) Children\u2019s Minnesota, Minneapolis, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melisa","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy (MR, KG, ML), Children\u2019s Minnesota, Minneapolis, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","published-online":{"date-parts":[[2024,6,10]]},"reference":[{"issue":"4","key":"2024061018373879000_i2331-348X-29-3-292-b01","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2217\/14750708.5.4.531","article-title":"Methylnaltrexone for the management of unwanted peripheral opioid effects","volume":"5","author":"Holzer","year":"2008","journal-title":"Therapy"},{"key":"2024061018373879000_i2331-348X-29-3-292-b02","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4137\/CMO.S4867","article-title":"Opioid-induced constipation in advanced illness: safety and efficacy of methylnaltrexone bromide","volume":"5","author":"Bader","year":"2011","journal-title":"Clin Med Insights Oncol"},{"key":"2024061018373879000_i2331-348X-29-3-292-b03","unstructured":"Methylnaltrexone\n          . Lexi-Drugs. Accessed August 23, 2020. http:\/\/online.lexi.com."},{"year":"2020","author":"Relistor [package insert]","key":"2024061018373879000_i2331-348X-29-3-292-b04"},{"issue":"5","key":"2024061018373879000_i2331-348X-29-3-292-b05","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jpain.2010.11.008","article-title":"Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study","volume":"12","author":"Michna","year":"2011","journal-title":"J Pain"},{"issue":"7","key":"2024061018373879000_i2331-348X-29-3-292-b06","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1089\/jpm.2014.0364","article-title":"Methylnaltrexone for opioid-induced constipation in children and adolescents and young adults with progressive incurable cancer at the end of life","volume":"18","author":"Flerlage","year":"2015","journal-title":"J Palliat Med"},{"issue":"10","key":"2024061018373879000_i2331-348X-29-3-292-b07","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/pbc.24615","article-title":"Methylnaltrexone for opioid-induced constipation in pediatric oncology patients","volume":"60","author":"Rodrigues","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2024061018373879000_i2331-348X-29-3-292-b08","doi-asserted-by":"crossref","first-page":"84","DOI":"10.12968\/jcyn.2008.2.2.28201","article-title":"Administering subcutaneous injection to children: what does the evidence say?","volume":"2","author":"Cocoman","year":"2008","journal-title":"J Child Young People Nurs"},{"issue":"4","key":"2024061018373879000_i2331-348X-29-3-292-b09","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0009-9236(97)90197-1","article-title":"The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time","volume":"61","author":"Yuan","year":"1997","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"2024061018373879000_i2331-348X-29-3-292-b10","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1177\/0091270004273491","article-title":"Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans","volume":"45","author":"Yuan","year":"2005","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"2024061018373879000_i2331-348X-29-3-292-b11","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/00000542-199710000-00008","article-title":"Opioid-induced delay in gastric emptying: a peripheral mechanism in humans","volume":"87","author":"Murphy","year":"1997","journal-title":"Anesthesiology"},{"issue":"3","key":"2024061018373879000_i2331-348X-29-3-292-b12","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1001\/jama.283.3.367","article-title":"Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial","volume":"283","author":"Yuan","year":"2000","journal-title":"JAMA"},{"issue":"1","key":"2024061018373879000_i2331-348X-29-3-292-b13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1136\/bmjspcare-2012-000291","article-title":"Paediatric palliative care: intravenous methylnaltrexone relieves constipation","volume":"3","author":"Yeomanson","year":"2013","journal-title":"BMJ Suppor Palliat Care"},{"issue":"2","key":"2024061018373879000_i2331-348X-29-3-292-b14","doi-asserted-by":"crossref","first-page":"F151","DOI":"10.1136\/archdischild-2011-300213","article-title":"Reversal of morphine-induced urinary retention after methylnaltrexone","volume":"97","author":"Garten","year":"2012","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"11","key":"2024061018373879000_i2331-348X-29-3-292-b15","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.2215\/CJN.01640309","article-title":"Measurement and estimation of GFR in children and adolescents","volume":"4","author":"Schwartz","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024061018373879000_i2331-348X-29-3-292-b16","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1007\/s00467-010-1598-7","article-title":"Validation of the revised Schwartz estimating equation in a predominantly non-CKD population","volume":"25","author":"Staples","year":"2010","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"2024061018373879000_i2331-348X-29-3-292-b17","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"2024061018373879000_i2331-348X-29-3-292-b18","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.cgh.2018.01.021","article-title":"Efficacy of treatments for opioid-induced constipation: Systematic review and meta-analysis","volume":"16","author":"Nee","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"2024061018373879000_i2331-348X-29-3-292-b19","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1089\/jpm.2014.0362","article-title":"Fixed-dose subcutaneous methynaltrexone in patients with advanced illness and opioid-induced constipation: results of a randomized, placebo-controlled study and open-label extension","volume":"18","author":"Bull","year":"2015","journal-title":"J Palliat Med"},{"issue":"2","key":"2024061018373879000_i2331-348X-29-3-292-b20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/jhm.943","article-title":"Subcutaneous methylnaltrexone for treatment of acute opioid-induced constipation: phase 2 study in rehabilitation after orthopedic surgery","volume":"7","author":"Anissian","year":"2012","journal-title":"J Hosp Med"},{"issue":"22","key":"2024061018373879000_i2331-348X-29-3-292-b21","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1056\/NEJMoa0707377","article-title":"Methylnaltrexone for opioid-induced constipation in advanced illness","volume":"358","author":"Thomas","year":"2008","journal-title":"N Eng J Med"},{"issue":"1","key":"2024061018373879000_i2331-348X-29-3-292-b22","first-page":"39","article-title":"Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients","volume":"7","author":"Slatkin","year":"2009","journal-title":"J Support Oncol"},{"issue":"4","key":"2024061018373879000_i2331-348X-29-3-292-b23","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1213\/01.ANE.0000148618.17736.3C","article-title":"The effects of a small-dose naloxone infusion on opioid-induced side effects and analgesia in children and adolescents treated with intravenous patient-controlled analgesia: a double-blind, prospective, randomized, controlled study","volume":"100","author":"Maxwell","year":"2005","journal-title":"Anesth Analg"},{"key":"2024061018373879000_i2331-348X-29-3-292-b24","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fnmol.2017.00174","article-title":"Pathophysiology of chemotherapy-induced peripheral neuropathy","volume":"10","author":"Starobova","year":"2017","journal-title":"Front Mol Neurosc"},{"key":"2024061018373879000_i2331-348X-29-3-292-b25","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1007\/s00277-020-04222-z","article-title":"Effect of lubiprostone on vinca alkaloid-induced constipation in patients with hematological malignancies: a propensity score-matched analysis","volume":"99","author":"Kawada","year":"2020","journal-title":"Ann Hematol"},{"issue":"1","key":"2024061018373879000_i2331-348X-29-3-292-b26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3109\/21556660.2013.838169","article-title":"Randomized placebo-controlled study of intravenous methylnaltrexone in postoperative ileus","volume":"2","author":"Viscusi","year":"2013","journal-title":"J Drug Assess"}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/29\/3\/292\/3385356\/i2331-348x-29-3-292.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/29\/3\/292\/3385356\/i2331-348x-29-3-292.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T18:41:58Z","timestamp":1738780918000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/29\/3\/article-p292.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,1]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,6,10]]},"published-print":{"date-parts":[[2024,6,1]]}},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-29.3.292","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"type":"electronic","value":"2331-348X"},{"type":"print","value":"1551-6776"}],"subject":[],"published":{"date-parts":[[2024,6,1]]}}}